VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

TCT 2021 | Cord blood-derived NK cells with high-dose chemotherapy & ASCT for B-NHL

Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a novel cellular ex vivo-expanded cord blood-derived NK cellular therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving high-dose chemotherapy and autologous stem cell transplantation (ASCT). The use of expanded and purified cord blood-derived NK cells, combined with high-dose chemotherapy and ASCT is safe and demonstrates early promising results in patients with B-NHL. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter